The human placenta produces a host of proteins which include human chorionic gonadotrophin (hCG) and human placental lactogen (hPL) as well as the new generation of pregnancy-associated plasma proteins (PAPP's) (Lin et al., 1974) . We do not know the biological role of these PAPP's and whether their synthesis is exclusively trophoblastic, or ectopic upon stimulation by pregnancy. The group is heterogeneous; M , values range from 21 600 (hPL) to 1 000 000 (pregnancy-associated plasma protein B, PAPP-B) and some members of the group are themselves heterogeneous in terms of electrophoretic mobility and M, (for a review see Bischof, 1984) . While pregnancy-specific PI -glycoprotein (SP,) is now accepted to be of genuinely trophoblastic origin, pregnancy-associated plasma protein A (PAPP-A) and pregnancy-associated a2-glycoprotein (az-PAC) have also been detected in the serum of non-pregnant women (Bischof et al., 1981; Bersinger & Klopper, 1984; Damber et ul., 1977) . A perfusion system in vitro with separate perfusion of fetal and maternal compartment in an isolated lobe of placenta provides information on the placental synthesis and release of PAPP's in the absence of maternal tissue. The aim of this study was to determine the rate of PAPP release as well as the net specific synthesis of hCG and the above-mentioned PAPP's in the presence and absence of two protein synthesis inhibitors in the perfusing medium.
A 2 6 5 0 g lobe of freshly delivered (spontaneously or by elective section) placenta was selected for perfusion. The chorionic vessels were cannulated for perfusion of the villous capillaries (fetal compartment). The maternal compartment was perfused with four to six fine needles introduced through the decidual surface into the intervillous space. This perfusion technique has been described before (Schneider P I al.. 1972). Both maternal and fetal circulations were first perfuscd for 1&15min in an open circuit and the venous return was discarded. Then the circuits were closed and the placenta was perfused with 120ml of buffer (33% Earle's medium with mixed amino acids, 6.30 mg/ml; human serum albumin, 40 mg/ml; dextran 40000, 10 mg/ml; clamoxyl, 0.5 mgiml). Every 30 min a 5 ml aliquot was removed from both circuits and replaced with fresh medium. After 30min
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closed perfusion, cycloheximide (final concn. 0.1 mg/ml; three placentae) or puromycin (final concn. 10 pg/ml; two placentae) was added. Five placentae were perfused without the addition of an inhibitor. After 3 h closed perfusion the experiment was stopped. The removed aliquots of medium were stored at -30°C until assayed for the PAPP's in batch. An aliquot of wet placental tissue ( 2 4 g ) was taken before and after perfusion and stored at -70°C. Later these tissues were homogenized with 4vol. of TBS (Tris/HCl), pH 7.4, 50mM; NaCI, l00mM) and the placental proteins were quantified in the supernatant after centrifugation.
The placental protein determinations were done by immunoassay; partially using commercially available radioimmunoassay kits (Serono Maiaclone for hCG; DPC Coat-aCount for hPL). SP, , PAPP-A, and a,-PAC were measured by enzyme-linked immunoadsorbent assay on microtitre plates and using peroxidase-labelled antibodies as tracers.
The results are presented in Table 1 . All amounts of placental proteins shown are expressed as values per g of perfused tissue. Values for hCG are in comparison with the standard 1st IRP 75/536, those for PAPP-A and a,-PAC are compared with the WHO pregnancy serum standard 78-610. In the maternal perfusate all five PAPP's were detected in increasing concentrations with perfusion time. On the fetal side, hCG, hPL and SP, were present and increasing while PAPP-A and a,-PAG could not be detected. The amount of released protein on the fetal side made up only 0.24.7% of the maternal quantity; this percentage was decreasing with increasing M , of the analyte (i.e. it was highest for hPL). The amounts of protein released into the medium during the interval between 60 and 180min of perfusion and per g of perfused tissue are given in Table 1 . The addition of puromycin significantly decreased the rate of hCG and PAPP-A release, while cycloheximide affected only hCG to such an extent. Overall, however, the release of all proteins tested was reduced by cycloheximide and puromycin. The variations from one placenta to another were considerable and most pronounced for a, -PAC, which corresponds to the observed patient-to-patient variations of serum PAPP concentrations during pregnancy in vivo (Bersinger et al., 1986) . In order to subtract a residual wash-out effect, the net specific synthesis (NSS) was calculated for each PAPP. This was done as described (Dancis et al., 1979) according to the formula: NSS = protein released + protein in perfused lobe -protein in the placenta before perfusion. Table 1 shows the results. In the absence of inhibitors, all five placentae synthesized hCG, hPL, SP, and PAPP-A, but in one placenta no a,-PAC was produced overall. The two inhibitors decreased all mean NSS values, with hCG and PAPP-A again most strongly affected. No PAPP-A was The transport of L-lactate and pyruvate into human erythrocytes can occur in three ways. At low concentrations of lactate, transport is mediated by a specific protogenic transport mechanism which can be inhibited by u-cyano-4-hydroxy-cinnamate derivatives, whilst at higher concentrations significant transport occurs via the general ion transporter (band 3) and by free diffusion of the undissociated acid (Halestrap, 1976; Deuticke, 1982 Thus in these experiments initial rates of uptake were calculated from the uptake at 15 s corrected for the dead time and any carrier-independent transport. The latter was determined by the apparent uptake in the presence of 5mh.ru-cyano-4-hydroxy-cinnamate which was shown in separate time course experiments to inhibit carrier-mediated transport more than 95% even at the highest [lactate] used (10 mM). For centrifuge stop measurements with erythrocytes the difference in uptake between 10 s and 30 s was used for the determination of rates.
From the time courses of uptake it was apparent that at 
